Mereo BioPharma Group plc (MREO) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $0.27, MREO has negative trailing earnings (P/E not meaningful) and an ROE of -74.76%. Market capitalisation stands at $42M.
Balance sheet quality for MREO: current ratio of 10.5, net cash position of $40.8M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $0.27 |
| Market Cap | $42M |
| Exchange | NASDAQ |
| Country | GB |
Valuation Ratios
| Price / Book | 1.44 |
| EV / EBITDA | -0.33 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -74.76% |
| Return on Invested Capital | -111.41% |
| Return on Assets | -80.88% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.04 |
| Current Ratio | 5.88 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -8.98 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| MREO | Mereo BioPharma Group plc | $42M | 1.44 | -74.8% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -15.02% |
| 3 months | -14.03% |
| Year-to-date | -36.17% |
| 1 year | -84.62% |
| 3 years | -81.78% |
| 5 years | -89.92% |
52-Week Range
| 52-week High | $2.37 |
| 52-week Low | $0.20 |
| Avg Volume (90d) | 4.5M |
Related companies: ACIU · ALDX · CADL · CAPR · CTNM · IMMP · KYTX
Explore sector: Healthcare · Biotechnology
More sections of MREO: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks